Abstract
Isavuconazole (ISAV) is a broad-spectrum triazole antifungal approved for the treatment of invasive aspergillosis and mucormycosis and has recently received approval for use in children ≥1 year of age. Pediatric approval was based on limited registration data, underscoring the importance of real-world evidence to better define efficacy and safety in children and adolescents. In this manuscript, we reviewed pediatric registration trials and real-world studies evaluating ISAV, with a focus on treatment and prophylaxis indications, pharmacokinetics, and safety. The literature review was conducted using PubMed, Embase, and Cochrane databases to identify relevant real-world and clinical studies published between January 1, 2005, and October 31, 2025. Studies reporting ISAV use in patients <18 years of age, including registration trials, observational cohorts, case series, and pharmacokinetic–pharmacodynamic studies, were included. Twenty-six real-world publications and two clinical registration trials met inclusion criteria. Among the real-world publications, ISAV was used for treatment in 23 studies and for prophylaxis in 5 studies, while 17 studies evaluated drug exposure or pharmacokinetics (several studies involved more than one mode of administration). Most patients had underlying hematologic or oncologic conditions. Across heterogeneous study populations and outcome definitions, complete or partial response was reported descriptively in approximately 72% of evaluable patients treated for invasive fungal disease, with breakthrough fungal infections reported in approximately 10% of patients receiving prophylaxis. Adverse events were generally mild and predominantly consisted of reversible hepatic laboratory abnormalities; serious drug-related toxicity, including one reported case of acute liver failure, was rare. Pharmacokinetic data demonstrated predictable exposure and achievement of target plasma concentrations in the majority of patients. Taken together, current evidence, although limited and derived largely from retrospective and salvage-treatment cohorts, suggests promising clinical activity and generally favorable tolerability of ISAV for invasive mold infections in pediatric populations. Real-world data support its use as a therapeutic option in selected patients, while underscoring the need for prospective studies to confirm efficacy, optimize dosing, and assess long-term safety.
Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1007/s40272-026-00780-3.
Key Points
| Broad-spectrum antifungal: ISAV is a triazole antifungal effective against Aspergillus spp. and Mucorales, with additional activity reported against select non-Aspergillus molds and some yeast, making it a valuable option for invasive fungal infections. |
| Favorable safety profile: ISAV is generally well tolerated in pediatric patients, it shows fewer drug–drug interactions, less hepatotoxicity, and does not prolong the QT interval. |
| Predictable pharmacokinetics: current literature shows generally predictable PK in most pediatric patients, with both IV and oral formulations available and high bioavailability allowing seamless intravenous–oral transition; routine therapeutic drug monitoring may not be necessary for most patients, although selective monitoring remains warranted in higher-risk scenarios. |
Introduction
Isavuconazole (ISAV) is a broad-spectrum triazole antifungal with activity against Aspergillus spp. and Mucorales, administered orally or intravenously as its water-soluble prodrug isavuconazonium sulfate. It has received regulatory approval in the United States (Food and Drug Administration [FDA], December 2023) and in Europe (European Medicines Agency [EMA], 2024) for use in pediatric patients aged ≥1 year, with formulation- and age-specific dosing recommendations [1]. Prior to pediatric regulatory approval, clinical experience with ISAV in children was limited primarily to case reports and small case series, in which it was most often used as salvage or step-down therapy. These reports suggested acceptable tolerability and potential clinical benefit; however, small sample sizes and heterogeneous study designs precluded robust conclusions regarding optimal dosing, pharmacokinetic–pharmacodynamic relationships, safety, and efficacy across pediatric age groups [2, 3].
In the absence of defined pediatric pharmacokinetic data, therapeutic drug monitoring (TDM) was frequently employed in clinical practice to guide dosing, reflecting concerns about interpatient variability. Compared with other triazole antifungals, ISAV is associated with a more favorable safety profile, including QTc interval shortening rather than prolongation, fewer clinically relevant drug–drug interactions, and a lower incidence of adverse events, most commonly mild elevations in liver function tests [4]. Its once-daily dosing regimen, predictable pharmacokinetics, and limited toxicity profile further support its potential utility in pediatric populations. Nonetheless, until recently, most findings on use in children have been extrapolated from adult studies, and key questions regarding real-world safety, tolerability, and the necessity of routine TDM in children remain incompletely defined [5].
The present study aims to review the pediatric registration trials and the contemporary literature on real-world ISAV use in children and adolescents, with a focus on treatment and prophylaxis, pharmacokinetic data, and adverse events.
Methods
This review was designed as a comprehensive narrative review. A structured literature search was conducted using PubMed, Embase, and the Cochrane Library to identify studies evaluating the efficacy, safety, and drug exposure of ISAV in patients between 1 and 17 years of age. The search strategy included (1) pediatric population terms (e.g., ‘child’, ‘pediatric’, ‘paediatric’, ‘adolescent’, ‘infant’, ‘neonate’, ‘toddler’), AND (2) underlying condition terms (e.g., ‘cancer’, ‘oncologic’, ‘hematologic’), AND (3) antifungal treatment/prophylaxis terms, AND (4) isavuconazole-specific terms (‘isavuconazole’ OR ‘isavuconazonium’), AND (5) fungal infection terms (e.g., ‘aspergillosis’, ‘mucormycosis’, ‘candidiasis’), and included as outcome ‘clinical efficacy’ OR ‘adverse events’ OR ‘pharmacokinetics’. This strategy yielded 2160 records before deduplication and covered publications from January 1, 2005, to October 31, 2025. Titles and abstracts were screened independently by two authors, followed by full-text assessment for eligibility. Reference lists of selected articles were manually screened to identify further eligible studies. No language restrictions were applied, while conference abstracts were excluded. The complete research strategy is reported in the electronic supplementary material (ESM), S1.
Eligible studies comprised observational studies (prospective and retrospective cohorts, case series, case reports, and letters to the editor), clinical trials, and pharmacokinetic–pharmacodynamic (PK/PD) investigations conducted in inpatient and outpatient pediatric populations. Extracted data included study design, patient characteristics, indication, dosing regimen, clinical response (defined as complete or partial response, as reported by the original studies; stable disease and disease progression were considered non-response, and response was extracted at the assessment timepoint reported by each study and according the current definitions [6]), incidence of breakthrough fungal infections, pharmacokinetic parameters, and the frequency and severity of adverse events, including serious adverse events (SAEs) [6–8]. Standard ISAV dosing was defined as a loading regimen of 5.4 mg/kg administered three times daily for the first 48 h, followed by a maintenance dose of 5.4 mg/kg once daily (maximum 200 mg). For isavuconazonium sulfate, standard dosing was defined as 10 mg/kg (maximum 372 mg) administered three times daily for 48 h as a loading dose, followed by 10 mg/kg once daily (maximum 372 mg) as maintenance therapy [9]. Results were interpreted descriptively without formal risk-of-bias assessment or quantitative meta-analysis. Accordingly, this article is a structured narrative review; summary figures such as overall response or breakthrough infection rates are reported as descriptive pooled counts across heterogeneous studies rather than as formal pooled efficacy estimates, and should be interpreted with corresponding caution. The study selection process is summarized in the flow diagram presented in Fig. 1.
Fig. 1.

Flowchart of the study selection process
Results
Registration Trials
The pediatric development of ISAV in patients aged 1–17 years, and its subsequent ultimate regulatory approval in this population was supported by two clinical trials conducted under pediatric investigation plans agreed upon by both the US FDA and the EMA [9, 10]. Evaluation in infants younger than 1 year of age was waived in accordance with regulatory determinations at the time.
Pediatric dose selection was initially guided by model-informed approaches extrapolated from adult pharmacokinetic data. A population pharmacokinetic model incorporating allometric scaling was used to simulate pediatric exposures across age and weight ranges, with the objective to achieve systemic exposures comparable to those observed in adults receiving the approved clinical dose. Based on these analyses, a weight-based dosing regimen of isavuconazonium sulfate (10 mg/kg, maximum 372 mg), administered every 8 h for the first 48 h and once daily thereafter, was predicted to provide adult-equivalent exposure in children and adolescents aged 1–17 years [9].
This dosing strategy was subsequently evaluated in a prospective, age-stratified phase I clinical trial in 46 immunocompromised pediatric patients, which confirmed comparable steady-state exposure to adults and an acceptable safety profile following intravenous or oral administration. Monte Carlo simulations demonstrated that the majority of pediatric patients achieved the predefined adult exposure target range (AUCss 60–233 µg·h/mL), supporting the suitability of the selected dosing regimen [9].
A second, phase II open-label, non-comparative, multicenter study further assessed the clinical outcomes, safety, and pharmacokinetics of ISAV in 31 children aged 1–17 years with proven, probable, or possible invasive aspergillosis or mucormycosis, the majority of whom had underlying hematologic malignancies [10]. Patients received weight-based isavuconazonium sulfate dosing (10 mg/kg, maximum 372 mg, equivalent to 5.4 mg/kg or 200 mg ISAV) for up to 84 days (invasive aspergillosis) or 180 days (mucormycosis). Overall response rates and mortality were consistent with adult experience, with successful overall response rate of 54.8% and day-42 all-cause mortality below 10% in this cohort. Most patients achieved adult-equivalent systemic exposure. Lower mean exposure was observed in the youngest age group, prompting exploratory simulations suggesting that higher dosing may improve target attainment in children younger than three years. ISAV was generally well tolerated; although treatment-emergent adverse events (TEAE) were common in this heavily immunocompromised population, permanent discontinuation due to drug-related toxicity was rare [11, 12].
Based on the two complementary trials, ISAV was approved by both FDA (2023) and EMA (2024) for targeted or preemptive treatment of invasive aspergillosis and mucormycosis in children aged ≥1 year (intravenous formulation) and ≥6 years (oral capsules), using age- and weight-adjusted dosing regimens without routine TDM. Of note, FDA dosing recommendations are based on isavuconazonium sulfate, whereas EMA recommendations are based on the active moiety, ISAV. In addition, due to the different regulatory interpretations of the pediatric pharmacokinetic data, the FDA-recommended intravenous dose for children aged 1 to <3 years is slightly higher than that recommended for other pediatric age groups [11, 12].
Real-World Evidence
Evidence Base and Patient Characteristics
Available real-world pediatric evidence on ISAV comprises retrospective multicenter studies, national observational cohorts, single-center case series, and individual case reports, encompassing a total of 286 children and adolescents across 26 studies. These 26 real-world publications are additional to, and reported separately from, the two pediatric registration trials described above (Sect. 1), which were identified directly as pre-specified regulatory trials rather than through the systematic database search. Although some studies originated from overlapping national networks, patient-level overlap between cohorts could not be excluded with certainty, representing a limitation of this review (see Discussion). Among the 26 real-world studies, 23 described ISAV treatment use [2, 3, 13–33], five studies reported antifungal prophylaxis [2, 33–36], and 17 included pharmacokinetic analyses [2, 3, 15, 17–27, 29, 35, 36]; several studies contributed data to more than one of these. Most studies were conducted in high-income countries (25/26), with a single study originating from a low–middle-income setting. Two studies were multicenter, while 24 reported single-center experiences.
Age distributions varied slightly across studies. The largest real-world cohort included 107 pediatric patients with a median age of 11 years (interquartile range, 6–14 years) [35]. Across the remaining cohorts, reported median ages ranged predominantly from 9 to 15 years, including patients aged 18 years. Infants and young children were primarily represented in small series and individual case reports, indicating that the current evidence base is largely weighted toward school-aged children and adolescents.
When reported, underlying conditions were predominantly hemato-oncological (23 of 26 studies), including hematological malignancies (140/286 patients) and non-malignant hematological disorders (19/286 patients). Transplantation-related immunosuppression was reported in six studies, comprising hematopoietic cell transplantation (HCT) in 78/286 patients and solid organ transplantation in seven patients. Other underlying conditions were infrequently documented and limited to isolated cases, including trauma (2/286 patients), inborn errors of immunity (10/286 patients), and other non-hematological conditions (4/286 patients).
Treatment Outcomes
ISAV was most commonly administered as salvage therapy following intolerance, contraindications, or insufficient response to other mold-active antifungal agents; first-line use was reported in a small number of cases. Reported treatment indications included invasive aspergillosis (14 studies [2, 3, 16, 18, 20, 21, 24, 25, 27, 28, 32–35]), mucormycosis (16 studies [2, 3, 13–15, 19, 21, 22, 25, 26, 29–33, 35]), other rare mold infections (3 studies [2, 25, 34]), and infections caused by other non-mold fungal pathogens (6 studies [3, 21, 23, 32, 34, 35]).
Clinical outcomes were reported heterogeneously across cohorts. In the multicenter cohort by Decembrino et al., outcomes were available for 24 of the 29 treated children, with complete or partial response in 70.8% (12/24 complete response, 5/24 partial response) [2].
In the largest real-world treatment cohort, Mendoza-Palomar et al. reported favorable outcomes for 26 of the 53 (49%) pediatric patients treated with ISAV for invasive fungal disease, including 25 complete responses and one partial response, while invasive fungal infection-related mortality was reported in 13 (24.5%) of the patients [35]. Additional single-center series described favorable response rates, including one cohort in which ~80% (21/26) of children treated for mucormycosis achieved complete response [21].
Smaller cohorts and case reports consistently documented clinical improvement or cure, including difficult-to-treat scenarios such as mucormycosis and central nervous system involvement, often in conjunction with surgical intervention and/or combination antifungal therapy (Table 1).
Table 1.
Demographics and clinical features of patients who received isavuconazole for antifungal treatment
| Study | Country | Center | No. of patients | Age (years, median) | Underlying condition | Dosage ISA: loadinga | Dosage ISA-P: loadinga | Dosage ISA: maintenancea | Dosage ISA-P: maintenancea | Route | Combined therapy | Monotherapy | First line/salvage therapy | Duration | Pathogens | Outcome |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Alali et al., 2022 [13] | USA/case report | Mono-center | 1 | 10 | HM | Not specified | Not specified | Oral | No | Yes | Salvage | >1 year | Mucorales | 1/1 CR | ||
| Ashkenazi-Hoffnung et al., 2020 [14] | Israel/case series | Mono-center | 4 | 10.5 (7–14) | HM, trauma | 3.5–5.6 mg/kg/dose (average 5 mg/kg daily) | IV and oral | Yes | Yes | Salvage | Average 2.5 months (2–4 months) | Mucorales | 4/4 CR | |||
| Brivio et al., 2019 [16] | Italy/case report | Mono-center | 1 | 16 | HM and HCT | Standard | Standard | IV | No | No | Salvage | 3 month | Aspergillus fumigatus | 0/1 discontinue for adverse event | ||
| Castagnola et al., 2020 [18] | Italy/case report | Mono-center | 1 | 12 | HM | Standard | Standard | IV | No | Yes | Salvage | 3 months | Aspergillus flavus | 1/1 CR | ||
| Nemoto et al., 2025 [28] | Japan/case report | Mono-center | 1 | 4 | Non-hematological conditions | 4.8 mg/kg ×3 daily × 48 h | 5.4 mg/kg once daily | IV | No | Yes | Salvage | 70 days | Aspergillus fumigatus | 1/1 CR | ||
| Shah et al., 2022 [30] | USA/case report | Mono-center | 1 | 17 | Trauma | Standard | Standard | IV | No | Yes | First line | 3 months | Mucorales | CR 1/1 | ||
| Sosnowska-Sienkiewicz et al., 2022 [31] | Norway/case report | Mono-center | 1 | 16 months | HM | Standard | Standard | IV | Yes | No | First line | 5 months | Mucorales | CR 1/1 | ||
| Styczynski et al., 2024 [32] | Poland/retrospective | Mono-center | 11 | 13 (1.5–17) | HM | Standard | Standard | IV and oral | Yes | Yes | Salvage | >1 year | Aspergillus, Mucorales, Candida | CR and PR 6/11 after 90 days | ||
| Zimmerman et al., 2022 [33] | France/retrospective | Mono-center | 9 | 9 (2–11) | HM |
f <30 kg: 100 mg ×3 for 48 h If >30 kg: 200 mg ×3 for 48 h |
<30 kg: 100 mg once daily >30 kg: 200 mg once daily |
IV and oral | Yes | No | Salvage | 90 days | Aspergillus, Mucorales | 3/9 PR, 6/9 CR at 90 days | ||
| Barg et al., 2018 [15] | Israel/case series | Mono-center | 3 | 4; 5; 19 | HM | 80–160 mg IV or 100–200 mg PO daily | oral | Yes | No | Salvage | >1 year | Mucorales | 1/1 CR | |||
| Cornu et al., 2018 [19] | France/case report | Mono-center | 1 | 3 | HMs | Standard | Standard | IV | Yes | Yes | Salvage | 24 months | Mucorales | 1/1 CR | ||
| De Leonardis et al., 2019 [20] | Italy/case report | Mono-center | 1 | 3 | HM | Standard | Standard | IV and oral | Yes | Yes | Salvage | 140 days | Probable Aspergillosis | 1/1 CR | ||
| Decembrino et al., 2020 [2] | Italy/retrospective | Multi-center | 24 | 14.5 (3–18) | HM and HCT | <30 kg: 100 mg q8h × 48 h; >30 kg: adult dose 200 mg q8h × 48 h | <30 kg: 100 mg/day; >30 kg 200 mg/once daily | IV and oral | Yes | Yes | 20/24 Salvage; 4/24 first line | Median 75.5 days (6–523) | Aspergillus, Mucorales, Penicillium |
12/24 CR and 5/24 PR Overall 70.8% (64.3% if only probable and proven IFI) 2/24 stable disease, 5/24 disease progression |
||
| Elhence et al., 2022 [21] | USA/retrospective | Mono-center | 26 | 11 (1–21) | HM | Standard | Standard | IV and oral | Not reported | Aspergillus, Mucorales, Candida | 21/26 CR | |||||
| Ferdjallah et al., 2021 [22] | USA/case series | Mono-center | 4 | 19 months, 2, 8, 11 year | HM and HCT | 7–15 mg/kg ×3 daily × 48 h | 7–15 mg/kg once daily | IV and oral | Yes | No | 1/3 salvage; 2/3 first line | Average 82 days (42–180) | Mucorales | 1/4 CR, 1/4 mortality IFI related, 2/4 mortality other causes | ||
| Garner et al., 2021 [24] | USA/case report | Mono-center | 1 | 16 | HCT | Standard | Standard | IV/G tube | No | Yes | First line | 183 days | Aspergillus | 1/1 CR | ||
| Fernández Ledesma et al., 2023 [25] | Spain/retrospective | Mono-center | 8 | 13 (6–14) | Hematologic and non-hematological conditions | Standard | Standard | IV and oral | Yes | No | Not reported | Not reported | Aspergillus, Fusarium, Mucorales | 4/8 CR | ||
| Loeffen et al., 2022 [26] | Netherlands/case series | Mono-center | 5 | 9 | HM | Not reported | Not reported | Not reported | Yes | No | Salvage | 8 months | Mucorales | 2/5 CR | ||
| Mendoza-Palomar et al., 2021 [27] | Spain/case report | Mono-center | 1 | 9 | Previously healthy | Not reported | Not reported | Not reported | Yes | No | Salvage | 365 days | Aspergillus fumigatus | 1/1 CR | ||
| Mendoza-Palomar et al., 2025 [35] | Spain/retrospective | Multi-center | 53 | 11 (6–14) | HM and non-hematological conditions | Not reported |
35 kg or less 5.4 mg/kg/day (max 200 mg) >35 kg 200 mg/day |
IV and oral | Yes | Yes | Salvage | Median 51 days (21–101) | Aspergillus, Mucorales, Candida, Trichosporon | 25/53 CR, 1/53 PR, 6/53 stable, 13/53 mortality IFI-related | ||
| Naeem et al., 2022 [23] | Lebanon/case report | Mono-center | 1 | 12 | Previously healthy | 200 mg (5.9 mg/kg) daily | 100 mg/day | oral | No | Yes | Salvage | >1 year | Coccidioides | 1/1 CR | ||
| Pomorska et al., 2018 [29] | Poland/case report | Mono-center | 1 | 7 | HM | Standard | Standard | IV | Yes | No | Salvage | 147 days | Mucorales | 1/1 CR | ||
| Ross et al., 2020 [3] | USA/retrospective | Mono-center | 11 | 14 (4–17) | HM and HCT | Standard | Standard | IV and oral | No | Yes | Not reported | Average 55 days | Aspergillus, Mucorales, Candida |
14 days: 5/11 PR, 3/11 stable 30 days: 5/11 PR, 4/11 stable 90 days: 6/11 PR or CR |
CR complete response, HCT hematopoietic cell transplantation, HM hematologic malignancies, IFI invasive fungal infection, ISA isavuconazole, ISA-P isavuconazonium, IV intravenous, PO orally, PR partial response, USA United States of America
aWe considered the standard dose for isavuconazonium to be 10 mg/kg and for isavuconazole 5.4 mg/kg administered 3 times a day for the first 48 h (loading dose) and then once daily (maintenance dose)
Across studies with evaluable outcome reporting, approximately 72% (142/199) of treated patients were reported as having complete or partial response, acknowledging substantial heterogeneity in patient populations, infection types, and treatment approaches, as well as a potential publication bias.
Prophylaxis Use and Breakthrough Infections
Real-world experience with ISAV used for antifungal prophylaxis in children was reported in five studies (Table 2). Across the available studies, a total of 49 pediatric patients (median age range, 9–15 years) received ISAV as prophylaxis, primarily in the setting of hematologic malignancy or stem cell transplantation. Prophylactic regimens varied with respect to dosing, duration, and route of administration, with both intravenous and oral formulations used, and weight-based dosing frequently applied. Overall, breakthrough invasive fungal infections during prophylaxis were reported in 5 of 49 patients, corresponding to an approximate breakthrough percentage of 10%. Specifically, three and two breakthrough infections occurred among 20 and 12 patients in the two largest pediatric cohorts, respectively [34, 35], whereas no breakthrough infections were reported in the three smaller cohorts [2, 33, 36].
Table 2.
Demographics and clinical features of patients who received isavuconazole for antifungal prophylaxis
| Author | Country | Center | No. of patients | Age (years, median) | Underlying condition | Dosage of ISA: loadinga | Dosage of ISA-P: loadinga | Dosage of ISA: maintenancea | Dosage of ISA-P: maintenancea | Route | Duration | Prophylaxis outcome: IFI breakthrough |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Decembrino et al., 2020 [2] | Italy/retrospective | Multi-center | 5 | 14.5 (3–18) | HM and HCT | <30 kg: 100 mg q8h × 48 h; >30 kg: adult dose 200 mg q8h × 48 h | <30 kg: 100 mg/day; >30 kg 200 mg/once daily | IV and oral | Mean 75 days | 0/5 | ||
| Kunvarjee et al., 2024 [34] | USA/retrospective | Mono-center | 20 | 14.8 (7–18) | HM and HCT | Standard | Standard | IV and oral | Not reported |
3/20 IFI: 1 proven (pathogen not available) and 2 probable/possible |
||
| Zimmerman et al., 2022 [33] | France/retrospective | Mono-center | 6 | 9 (2–11) | HM |
f <30 kg: 100 mg ×3 for 48 h If >30 kg: 200 mg ×3 for 48 h |
<30 kg: 100 mg once daily >30 kg: 200 mg once daily |
IV and oral | 90 days | 0/6 | ||
| Gatti et al., 2022 [36] | Italy/retrospective | Mono-center | 6 | 9.5 | HM | 100 mg ×3/die × 24 h | 100 mg once daily | Not reported | 174 days | 0/6 | ||
| Mendoza-Palomar et al., 2025 [35] | Spain/retrospective | Multi-center | 12 | 11 (6–14) | HM and non-hematological conditions | Not reported |
35 kg or less 5.4 mg/kg/day (max 200 mg) >35 kg 200 mg/day |
IV and oral | Median 51 days (21–101) | 0/12 |
HCT hematopoietic cell transplantation, HM hematologic malignancies, IFI invasive fungal infection, ISA isavuconazole, ISA-P isavuconazonium, IV intravenous, USA United States of America
aWe considered the standard dose for isavuconazonium was 10 mg/kg and for isavuconazole, 5.4 mg/kg administered three times a day for the first 48 h (loading dose) and then once daily (maintenance dose)
Safety and Tolerability
Safety data were reported in 11 of the 26 studies [2, 3, 16, 19, 21–23, 25, 33–35], with the most informative data derived from larger cohorts (Table 3). Overall, ISAV was generally well tolerated in pediatric patients, with adverse events predominantly consisting of mild to moderate laboratory abnormalities.
Table 3.
Demographics and clinical features of patients who presented adverse events during isavuconazole administration in therapeutic or prophylactic indications
| Author | Country | Center | No. of patientsa | Age (years, median) | Underlying condition | No. of patients with underling conditions | Dosage of ISA: loadingb | Dosage of ISA-P: loadingb | Dosage of ISA: maintenanceb | Dosage of ISA-P: maintenanceb | Route | Duration | Type of adverse events (free text) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kunvarjee et al., 2024 [34] | USA/retrospective | Mono-center | 26 | 14.8 (7–18) | HM and HCT | HM: 24, HCT: 2 | Standard | Standard | IV and oral | Not reported | 6/26 AST or ALT | ||
| Alali et al., 2022 [13] | USA/case report | Mono-center | 1 | 10 | HM | HM: 1 | Not specified | Not specified | Oral | >1 year | Not reported | ||
| Ashkenazi-Hoffnung et al., 2020 [14] | Israel/case series | Mono-center | 4 | 10.5 (7–14) | HM, trauma | HM: 3, trauma: 1 | 3.5–5.6 mg/kg/dose (average 5 mg/kg daily) | IV and oral | Average 2.5 months (2–4 months) | Not reported | |||
| Brivio et al., 2019 [16] | Italy/case report | Mono-center | 1 | 16 | HM and HCT | HCT: 1 | Standard | Standard | IV | 3 months | 1/1 hepatitis | ||
| Castagnola et al., 2020 [18] | Italy/case report | Mono-center | 1 | 12 | HM | HM: 1 | Standard | Standard | IV | 3 months | Not reported | ||
| Nemoto et al., 2025 [28] | Japan/case report | Mono-center | 1 | 4 | Non-hematological conditions | Non-hematological conditions: 1 | 4.8 mg/kg × 3 daily × 48 h | 5. 4 mg/kg once daily | IV | 70 days | Not reported | ||
| Shah et al., 2022 [30] | USA/case report | Mono-center | 1 | 17 | Trauma | Trauma: 1 | Standard | Standard | IV | 3 months | Not reported | ||
| Sosnowska-Sienkiewicz et al., 2022 [31] | Norway/case report | Mono-center | 1 | 16 months | HM | HM: 1 | Standard | Standard | IV | 5 months | Not reported | ||
| Styczynski et al., 2024 [32] | Poland/retrospective | Mono-center | 14 | 13 (1.5–17) | HM and HCT | HM: 10, HCT: 4 | Standard | Standard | IV and oral | >1 year | Not reported | ||
| Zimmerman et al., 2022 [33] | France/retrospective | Mono-center | 15 | 9 (2–11) | HM and non- hematological conditions | HM: 11; non-malignant hematological diseases: 4 |
If < 30 kg: 100 mg ×3 for 48 h If >30 kg: 200 mg ×3 for 48 h |
<30 kg: 100 mg once daily >30 kg: 200 mg once daily |
IV and oral | 90 days | Elevation of AST and ALT in 3/9; creatinine serum level was elevated in 3/9 | ||
| Gatti et al., 2022 [36] | Italy/retrospective | Mono-center | 6 | 9.5 | HM | HM: 6 | 100 mg × 3/die × 24 h | 100 mg once daily | Not reported | 174 days | Not reported | ||
| Barg et al., 2018 [15] | Israel/case series | Mono-center | 3 | 4; 5; 19 | HM | HM: 3 | 80–160 mg IV or 100–200 mg PO daily | Oral | >1 year | Not reported | |||
| Bury et al., 2023 [17] | Netherlands/prospective | Mono-center | 17 | 9 (1–17) | HM | HM: 17 | Standard | Standard | IV and oral | 11–546 days | Not reported | ||
| Cornu et al., 2018 [19] | France/case report | Mono-center | 1 | 3 | HM | HM: 1 | Standard | Standard | IV | 24 months | 1/1 nausea/vomiting | ||
| De Leonardis et al., 2019 [20] | Italy/case report | Mono-center | 1 | 3 | HM | HM: 1 | Standard | Standard | IV and oral | 140 days | Not reported | ||
| Decembrino et al., 2020 [2] | Italy/retrospective | Multi-center | 29 | 14.5 (3–18) | HM and HCT | HM 10; HCT: 19 | <30 kg: 100 mg q8h × 48 h; >30 kg: adult dose 200 mg q8h × 48 h | <30 kg: 100 mg/day; >30 kg: 200 mg/once daily | IV and oral | Median 75.5 days (6–523) | 6/29: transaminase elevation, creatinine rise; bilirubin increase | ||
| Elhence et al., 2022 [21] | USA/retrospective | Mono-center | 26 | 11 (1–21) | HM | HM: 22, other not specified: 4 | Standard | Standard | IV and oral | Not reported | 13/26 increases in liver enzymes | ||
| Ferdjallah et al., 2022 [22] | USA/case series | Mono-center | 4 | 19 months, 2, 8, 11 year | HM and HCT | HCT: 4 | 7–15 mg/kg × 3 daily × 48 h | 7–15 mg/kg once daily | IV and oral | Average 82 days (42–180) | 1/4 increase ALT and AST | ||
| Garner et al., 2021 [24] | USA/case report | Mono-center | 1 | 16 | HCT | HCT: 1 | Standard | Standard | IV/G tube | 183 days | Not reported | ||
| Fernández Ledesma et al., 2023 [25] | Spain/retrospective | Mono-center | 14 | 13 (6–14) | Hematologic and non-hematological conditions | HM: 3, HCT: 8, other non-hematological: 3 | Standard | Standard | IV and oral | Not reported | 1/4 increased liver enzymes | ||
| Loeffen et al., 2022 [26] | Netherlands/case series | Mono-center | 7 | 9 | HM | HM: 7 | Not reported | Not reported | Not reported | 8 months | Not reported | ||
| Mendoza-Palomar et al., 2021 [27] | Spain/case report | Mono-center | 1 | 9 | Previously healthy | Not reported | Not reported | Not reported | 365 days | Not reported | |||
| Mendoza-Palomar et al., 2025 [35] | Spain/retrospective | Multi-center | 107 | 11 (6–14) | HM and non-hematological conditions | HM: 19, HCT: 46, SOT 7, inborn errors of immunity: 10, non-malignant hematological diseases: 15, other: 10 | Not reported | ≤35 kg: 5.4 mg/kg/day (max 200 mg) >35 kg: 200 mg/day | IV and oral | Median 51 days (21–101) | 14/107 liver toxicity; 5/107 gastrointestinal toxicity; 2/107 renal toxicity | ||
| Naeem et al., 2020 [23] | Lebanon/case report | Mono-center | 1 | 12 | Previously healthy | 200 mg (5.9 mg/kg) daily | 100 mg/day | Oral | >1 year | 1/1 chest pain and nausea | |||
| Pomorska et al., 2018 [29] | Poland/case report | Mono-center | 1 | 7 | HM | HM: 1 | Standard | Standard | IV | 147 days | Not reported | ||
| Ross et al., 2020 [3] | USA/retrospective | Mono-center | 11 | 14 (4–17) | HM and HCT | Not clearly available | Standard | Standard | IV and oral | Average 55 days | 4/18 elevated ALT |
ALT alanine transaminases, AST aspartate transaminases, AUC0–24h area under concentration–time curve from 0 to 24 h, CI confidence interval, Cmin minimum concentration, Ctrough concentration trough level, HCT hematopoietic cell transplantation, HM hematologic malignancies, IQR interquartile range, ISA isavuconazole, ISA-P isavuconazonium, IV intravenous, PK pharmacokinetics, PO orally, SOT solid organ transplantation, USA United States of America
aWe reported the overall number of patients described in the study for treatment or prophylaxis regimen
bWe considered the standard dose for isavuconazonium to be 10 mg/kg and for isavuconazole, 5.4 mg/kg administered three times a day for the first 48 h (loading dose) and then once daily (maintenance dose)
Across these 11 studies, a total of 61 separate adverse event episodes were identified among 266 evaluable patients. In the largest real-world pediatric cohort (107 patients), adverse events included hepatic laboratory abnormalities in approximately 13% of patients, gastrointestinal events in approximately 5%, and renal laboratory abnormalities in approximately 2% [35].
In a multicenter cohort of 29 children, adverse events, mainly transaminase elevations, bilirubin increases, or creatinine elevations, were reported in approximately 21% of patients [2]. Other cohorts reported ALT and/or AST elevations in 20–50% of evaluable patients [3, 21]. Gastrointestinal adverse events, including nausea and vomiting, were infrequent and generally mild. One case report described isavuconazole-induced acute liver failure requiring drug discontinuation in a pediatric patient with invasive aspergillosis, underscoring that although rare, severe hepatotoxicity can occur and warrants clinical vigilance, particularly in patients receiving other hepatotoxic agents. Aside from this case, no consistent signal for unexpected or novel toxicities was identified across studies. Overall, the pediatric safety profile of ISAV in real-world use appears broadly consistent with that observed in adults, with reversible hepatic enzyme elevations representing the most commonly reported adverse events.
Pharmacokinetics and the Role of Therapeutic Drug Monitoring
Pharmacokinetic and TDM data were reported in 17 pediatric studies [2, 3, 15, 17–27, 29, 35, 36], primarily derived from real-world clinical practice (Table 4). Across cohorts, median or mean trough concentrations (Ctrough) of ISAV generally ranged between 2.9 and 3.6 µg/mL, with steady-state exposure typically achieved within 7–9 days of treatment initiation. These exposure levels are comparable to those observed in adult populations receiving standard dosing regimens.
Table 4.
Demographics and clinical features of patients with pharmacokinetic analyses for isavuconazole in therapeutic or prophylactic indication
| Author | Country | Center | No. of patientsa | Age (years, median) | Underlying condition | Dosage of ISA: loadingb | Dosage of ISA-P: loadingb | Dosage of ISA: maintenanceb | Dosage of ISA-P: maintenanceb | Route | PK outcomes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Castagnola et al., 2020 [18] | Italy/case report | Mono-center | 1 | 12 | HM | Standard | Standard | IV | Cmin >2 mg/L (not specified day) | ||
| Gatti et al., 2022 [36] | Italy/retrospective | Mono-center | 6 | 9.5 | HM | 100 mg ×3/die × 24 h | 100 mg once daily | Not reported | Average Cmin (mg/L, day 7): 2.9 (1.9–3.5) | ||
| Barg et al., 2018 [15] | Israel/case series | Mono-center | 3 | 4; 5; 19 | HM | 80–160 mg IV or 100–200 mg PO daily | Oral | Cmin (ng/mL, day 5th): 1.4 | |||
| Bury et al., 2023 [17] | Netherlands/prospective | Mono-center | 17 | 9 (1–17) | HM | Standard | Standard | IV and oral | Median (IQR) simulated AUC0–24h: IV 87.7 mg/h/L (95% CI 70.5–105.1); oral/nasogastric tube 50.3 mg/h/L (95% CI 39.0–62.4) | ||
| Cornu et al., 2018 [19] | France/case report | Mono-center | 1 | 3 | HM | Standard | Standard | IV | Cmin (μg/mL, day 7): 1110 | ||
| De Leonardis et al., 2019 [20] | Italy/case report | Mono-center | 1 | 3 | HM | Standard | Standard | IV and oral | Cmin (mg/L, day 7): 2.9 | ||
| Decembrino et al., 2020 [2] | Italy/retrospective | Multi-center | 29 | 14.5 (3–18) | HM and HCT | <30 kg: 100 mg q8h × 48 h; >30 kg: adult dose 200 mg q8h × 48 h | <30 kg: 100 mg/day; >30 kg 200 mg once daily | IV and oral | Cmedian (mg/L): 4.91 (2.15–8.54) | ||
| Elhence et al., 2022 [21] | USA/retrospective | Mono-center | 26 | 11 (1–21) | HM | Standard | Standard | IV and oral | Cmedian (mg/L, day 3): 3.8 mg/L (3.1–5.6 mg/L) | ||
| Ferdjallah et al., 2021 [22] | USA/case series | Mono-center | 4 | 19 months, 2, 8, 11 year | HM and HCT | 7–15 mg/kg × 3 daily × 48 h | 7–15 mg/kg once daily | IV and oral | Cmedian (mg/L, day 5): 3.25 | ||
| Garner et al., 2021 [24] | USA/case report | Mono-center | 1 | 16 | HCT | Standard | Standard | IV/G tube | Cmin (ng/mL, day 37): 0.6 μg/mL | ||
| Fernández Ledesma et al., 2023 [25] | Spain/retrospective | Mono-center | 8 | 13 (6–14) | Hematologic and non-hematological conditions | Standard | Standard | IV and oral | Median Ctrough (μg/mL, day 9): 3.6 (IQR 2.5–4.6) | ||
| Loeffen et al., 2022 [26] | Netherlands/case series | Mono-center | 7 | 9 | HM | Not reported | Not reported | Not reported | Median Ctrough (μg/mL, day not specified): 4 mg/L | ||
| Mendoza-Palomar et al., 2021 [27] | Spain/case report | Mono-center | 1 | 9 | Previously healthy | Not reported | Not reported | Not reported | Range Ctrough (μg/mL): 2.5–5 | ||
| Mendoza-Palomar et al., 2025 [35] | Spain/retrospective | Multi-center | 107 | 11 (6–14) | HM and non-hematological conditions | Not reported |
35 kg or less 5.4 mg/kg/day (max 200 mg) >35 kg 200 mg/day |
IV and oral | Median Ctrough (mg/L at day 8): 3.1 (IQR 2.1–4.9 | ||
| Naeem et al., 2020 [23] | Lebanon/case report | Mono-center | 1 | 12 | Previously healthy | 200 mg (5.9 mg/kg) daily | 100 mg/day | Oral | Range Ctrough (μg/mL): 3.3–4.5 μg/mL | ||
| Pomorska et al., 2018 [29] | Poland/case report | Mono-center | 1 | 7 | HM | Standard | Standard | IV | Cmin (μg/mL, day 7): 2.45 μg/mL | ||
| Ross et al., 2020 [3] | USA/retrospective | Mono-center | 11 | 14 (4–17) | HM and HCT | Standard | Standard | IV and oral | Cmin (μg/mL, day 4): 3.6 (0.4–7.4) |
AUC0–24h area under concentration–time curve from 0 to 24 h, CI confidence interval, Cmin minimum concentration, Ctrough concentration trough level, HCT hematopoietic cell transplantation, HM hematologic malignancies, IQR interquartile range, ISA isavuconazole, ISA-P isavuconazonium, IV intravenous, PK pharmacokinetics, USA United States of America
aWe reported the overall number of patients described in the study for treatment or prophylaxis regimen
bWe considered the standard dose for isavuconazonium to be 10 mg/kg and for isavuconazole, 5.4 mg/kg administered three times a day for the first 48 h (loading dose) and then once daily (maintenance dose)
Substantial inter-patient variability in systemic exposure was observed. Reduced systemic exposure was consistently reported in children receiving non-standard oral administration, particularly when ISAV capsules were opened and administered via nasogastric or gastrostomy tubes. In the largest pediatric pharmacokinetic cohort to date, 76 of 95 patients were evaluated, with ISAV concentrations from 330 distinct trough samples analyzed. The authors reported a median ISAV Ctrough of 3.1 µg/mL (IQR 2.1–4.9), with 195 of 330 Ctrough values falling outside the therapeutic target range. Nevertheless, 64 out of 76 patients achieved therapeutic concentrations, reported as 2.5–5 µg/mL [35].
Similar exposure distributions were reported in smaller cohorts with a median Ctrough of 4.9 µg/mL and 3.8 µg/mL, respectively [2, 21]. Although younger children were underrepresented in larger cohorts, available data suggest greater pharmacokinetic variability in this age group. Together with observations of altered gastrointestinal absorption and modified drug administration, it is indicated that closer attention to dosing and consideration of selective TDM may be warranted in specific clinical scenarios rather than as a routine measure.
Discussion and Perspectives
This review summarizes the available evidence on the use of ISAV in pediatric patients and places current findings within the broader context of the increasing burden of invasive fungal infections and the need for optimized antifungal strategies in children. The generation of high-quality data on antifungal pharmacokinetics, pharmacodynamics, and safety, particularly in vulnerable pediatric populations, has been identified as a key priority within the World Health Organization research agenda for fungal infections [37]. Our review contextualizes the recent regulatory approval of ISAV in Europe for pediatric use since 2024, following authorization by the European Medicines Agency for the treatment of invasive infections caused by Aspergillus spp. and Mucorales [11].
Available pediatric data on ISAV largely focus on treatment indications, with comparably limited data supporting its use for antifungal prophylaxis. Across real-world cohorts, ISAV demonstrated clinically meaningful activity in pediatric invasive fungal disease. The largest real-world pediatric cohort to date, published by Mendoza-Palomar et al., included 53 children and adolescents and demonstrated clinical response or disease stabilization in approximately 60% of patients [35]. Comparable outcomes were reported in other cohorts, including the study by Decembrino et al., which documented a 70% response rate, and the smaller series reported by Ross et al., in which approximately 60% achieved response or stabilization [2, 3].
Taken together, these findings suggest clinically meaningful antifungal activity of ISAV in pediatric invasive fungal infections, despite heterogeneity in study design, patient populations, infection types, and outcome definitions. Importantly, the observed outcomes must be interpreted in the context of real-world prescribing patterns. Across the reviewed studies, ISAV was most frequently administered as salvage therapy, typically in children with advanced fungal disease, prior antifungal exposure, intolerance or drug–drug interactions, or contraindications to other mold-active agents. This treatment positioning aligns with current pediatric EMA indications and likely contributes to the moderate response rates observed in several cohorts [11]. Nonetheless, the consistent documentation of clinical improvement or disease stabilization in heavily pretreated and immunocompromised children supports the role of ISAV as a valuable therapeutic option in complex clinical scenarios. These observations should be regarded as promising real-world experience rather than proven efficacy: most data derive from small, heterogeneous, retrospective, and salvage-treatment cohorts with variable outcome definitions, and are subject to confounding by indication and potential publication bias favoring successful cases (Table 5).
Table 5.
Practical clinical guidance for isavuconazole use in pediatric patients
| Aspect | Clinical guidance |
|---|---|
| Approved age and formulation | IV: ≥1 year (FDA, Dec 2023; EMA 2024). Oral capsules: age/weight-eligible children, generally ≥6 years per FDA labeling |
| Standard dosing | Isavuconazonium sulfate 10 mg/kg (max 372 mg, equivalent to isavuconazole 5.4 mg/kg, max 200 mg) three times daily for 48 h (loading), then once daily (maintenance) |
| When to consider ISAV | Targeted/preemptive treatment of invasive aspergillosis or mucormycosis; salvage therapy after intolerance, contraindication, or failure of other mold-active agents; patients needing fewer drug–drug interactions or oral-IV switch |
| When to avoid or monitor closely | Known hypersensitivity; short QT syndrome (theoretical); pre-existing significant hepatic impairment; concurrent hepatotoxic agents (monitor closely rather than avoid outright) |
| When to consider selective TDM | Very young age; altered gastrointestinal absorption or enteral-tube administration; intensive care; hepatic dysfunction; suspected toxicity; breakthrough infection or treatment failure; major drug–drug interactions; prophylaxis in high-risk hemato-oncology/HCT patients |
| Key drug–drug interactions | Moderate CYP3A4 inhibitor: monitor/adjust calcineurin inhibitors (tacrolimus, cyclosporine), sirolimus, and chemotherapeutic agents metabolized via CYP3A4; fewer interactions than voriconazole or posaconazole overall |
| Hepatic monitoring | Baseline and periodic liver function tests recommended, particularly with concomitant hepatotoxic chemotherapy, conditioning regimens, or prolonged therapy; rare severe hepatotoxicity (including acute liver failure) has been reported |
| QTc considerations | Associated with QTc shortening rather than prolongation; may be preferred over other azoles when baseline QTc prolongation is a concern, with routine cardiac monitoring per institutional protocol |
| Formulation limitations | Reduced systemic exposure reported when capsules are opened for nasogastric/gastrostomy administration; IV formulation preferred during mucositis or when oral absorption is uncertain |
This table summarizes practical guidance synthesized from the registration trials and real-world evidence reviewed in this article and does not replace institutional protocols or product labeling
DDI drug–drug interaction, EMA European Medicines Agency, FDA Food and Drug Administration, HCT hematopoietic cell transplantation, ISAV isavuconazole, IV intravenous, TDM therapeutic drug monitoring
In contrast to the treatment of invasive fungal diseases, evidence supporting the use of ISAV for antifungal prophylaxis in pediatric patients remains limited. Despite isolated reports of breakthrough fungal infections during ISAV prophylaxis in children, conclusions regarding efficacy are constrained by small sample sizes and heterogeneous prophylactic strategies in these studies [2, 3, 15, 19, 20, 29, 33]. Data from adult studies suggest variable prophylactic efficacy of ISAV compared with established agents such as posaconazole and voriconazole, particularly in HCT settings [38, 39]. Although recent ECIL-10 guidelines include ISAV as a prophylactic option in selected adult hematologic populations, ISAV is not approved for antifungal prophylaxis in either adults or children. Corresponding pediatric evidence remains insufficient to support routine prophylactic use; given the small and heterogeneous evidence base, and the availability of better-established pediatric prophylaxis options such as posaconazole and voriconazole in selected populations, ISAV-based prophylaxis should be considered on an individualized basis rather than as routine practice, underscoring the need for further dedicated pediatric studies [40].
Safety data across the reviewed pediatric studies consistently indicate a favorable tolerability profile. Reported adverse events were predominantly mild to moderate and mainly consisted of reversible laboratory abnormalities, particularly transient elevations in liver enzymes. Serious drug-related adverse events leading to permanent discontinuation were rare; however, one published pediatric case of isavuconazole-induced acute liver failure illustrates that severe hepatotoxicity, although uncommon, can occur, particularly in patients receiving other hepatotoxic agents such as chemotherapy, transplant conditioning regimens, or calcineurin inhibitors. Given the limited number of pediatric patients and the retrospective nature of most reports, continued vigilance and systematic safety assessment remain essential.
Pharmacokinetic analyses further support the feasibility of weight-based dosing strategies in children. Across studies, ISAV exposure levels were generally comparable to those observed in adult populations receiving standard dosing regimens [10]. Nonetheless, substantial interpatient variability was noted, particularly in younger children and in those receiving non-standard oral administration, such as capsule opening with enteral tube delivery. While proposed therapeutic concentration targets have largely been extrapolated from adult data, accumulating evidence suggests that routine therapeutic drug monitoring of ISAV may not be necessary in most pediatric patients. Selective, rather than routine, monitoring is more appropriate, and should be considered in specific higher-risk scenarios, including very young age, altered gastrointestinal absorption or enteral-tube administration, intensive care, hepatic dysfunction, suspected toxicity, breakthrough infection or treatment failure, major drug–drug interactions, and prophylaxis in high-risk hemato-oncology or HCT patients [5, 9, 41, 42]. Ongoing clinical trials are expected to further clarify optimal dosing strategies, safety, and exposure–response relationships in pediatric populations [43].
Considerations in Pediatric Hemato-Oncology and Hematopoietic Cell Transplantation Practice
The majority of pediatric patients described in this review had underlying hematologic malignancy or underwent HCT, populations in which the clinical use of ISAV carries specific practical considerations. Its comparatively favorable drug–drug interaction profile relative to voriconazole and posaconazole is particularly relevant in this setting, where children frequently receive concomitant calcineurin inhibitors (e.g., tacrolimus, cyclosporine) for graft-versus-host disease prophylaxis or treatment, together with chemotherapeutic agents and other CYP3A4-metabolized drugs; nonetheless, monitoring of calcineurin inhibitor levels and dose adjustment remain advisable when ISAV is co-administered. Gastrointestinal mucositis, a common complication of intensive chemotherapy and conditioning regimens, may impair oral absorption of ISAV capsules and likely contributes to the reduced systemic exposure observed with non-standard administration routes, such as capsule opening for enteral-tube delivery, reinforcing the value of the intravenous formulation during periods of mucosal toxicity [44]. Hepatic toxicity warrants particular vigilance in this population given frequent concurrent exposure to hepatotoxic chemotherapy, transplant conditioning regimens, and other potentially hepatotoxic agents; the reported case of isavuconazole-induced acute liver failure occurred in a child undergoing HCT who had invasive aspergillosis, underscoring the importance of baseline and periodic liver function monitoring, particularly during prolonged neutropenia or cellular therapy courses. Finally, in high-risk hemato-oncology and HCT populations, antifungal prophylaxis strategies should continue to rely preferentially on agents with more established pediatric evidence, such as posaconazole or voriconazole, reserving ISAV-based prophylaxis for individualized use pending further prophylaxis-specific pediatric data [45].
Conclusion
This review provides a contemporary and comprehensive synthesis of pediatric registration trials and real-world experience with isavuconazole, integrating data on treatment, prophylaxis, pharmacokinetics, and safety across diverse clinical settings. By summarizing available evidence up to October 2025, it offers an updated overview of current practice patterns and highlights emerging pharmacokinetic considerations in children. However, several limitations should be acknowledged. Most available data derive from retrospective, single-center studies, case series, and case reports, which are subject to selection bias and incomplete reporting. Considerable heterogeneity exists regarding patients, response criteria, dosing strategies, and pharmacokinetic targets. Younger children and pediatric patients from low- and middle-income settings remain underrepresented. As a narrative review without formal risk-of-bias assessment or meta-analysis, findings are descriptive in nature. These considerations underscore the need for well-designed prospective cohorts and real-time multicenter registries using standardized definitions and systematic pharmacokinetic and safety monitoring to better define optimal dosing, exposure–response relationships, and long-term future outcomes in pediatric populations.
Supplementary Information
Below is the link to the electronic supplementary material.
Funding
Open Access funding enabled and organized by Projekt DEAL. The authors received no specific funding for this work.
Declarations
Conflict of Interest
A.H. Groll has received grants from Gilead; served as a consultant to Basilea, Mundipharma, and Pfizer; received payment or honoraria from Basilea, Gilead, Merck, Merck Sharp & Dohme, Mundipharma, Novartis, and Pfizer; received payment for expert testimony from Mundipharma and Pfizer; and participated in the Safety Monitoring Board or Advisory Board for Astellas. The other authors declare that they have no conflict of interest.
Use of Artificial Intelligence (AI)
During the preparation of this manuscript, the authors used [Claude/Gemini] solely to improve the clarity and grammatical correctness of the English language in selected sentences. The tool was not used to generate, analyze, or interpret data, nor to draft scientific content, conclusions, or references. After using this tool, the authors have reviewed and edited all text as needed and all authors take full responsibility for the content of the publication.
Availability of Data and Material
Data are contained within the article.
Ethics Approval
Ethical approval not applicable for the type of study. The study was performed in accordance with the ethical standards as laid down in the 1964 Declaration of Helsinki and its later amendments or comparable ethical standards.
Consent to Participate
Not applicable.
Consent for Publication
Not applicable.
Code Availability
Not applicable.
Author Contributions
A.G. and Z.D.P. conceived the presented review; L.C. and L.M. contributed to the literature search, screened literature for study selection, and conducted data collection; L.C., A.G., and Z.D.P. study selection; L.C. performed formal analysis and wrote the first draft of the manuscript with input from all authors; L.C., A.G, K.L., L.M., D.E.F, D.S. and Z.D.P. aided in interpreting the results and revised the manuscript. All authors have read and agreed to the published version of the manuscript.
Footnotes
Andreas H. Groll and Zoi Dorothea Pana contributed equally.
References
- 1.European Medicines Agency (EMA). Cresemba [Internet]. 2025 [cited 2025 May 14]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba.
- 2.Decembrino N, Perruccio K, Zecca M, et al. A case series and literature review of isavuconazole use in pediatric patients with hemato-oncologic diseases and hematopoietic stem cell transplantation. Antimicrob Agents Chemother. 2020;64(3):1–10. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Ross JA, Karras NA, Tegtmeier B, et al. Safety of isavuconazonium sulfate in pediatrics patients with hematologic malignancies and hematopoietic cell transplantation with invasive fungal infections: a real world experience. J Pediatr Hematol Oncol. 2020. 10.1097/MPH.0000000000001787. [DOI] [PubMed] [Google Scholar]
- 4.Mellinghoff SC, Bassetti M, Dörfel D, et al. Isavuconazole shortens the QTc interval. Mycoses. 2018. 10.1111/myc.12731. [DOI] [PubMed] [Google Scholar]
- 5.Risum M, Vestergaard MB, Weinreich UM, et al. Therapeutic drug monitoring of isavuconazole: serum concentration variability and success rates for reaching target in comparison with voriconazole. Antibiotics (Basel). 2021. 10.3390/antibiotics10050487. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 6.Segal BH, Herbrecht R, Stevens DA, et al. Defining responses to therapy and study outcomes in clinical trials of invasive fungal diseases: Mycoses Study Group and European Organization for Research and Treatment of Cancer Consensus Criteria. Clin Infect Dis. 2008. 10.1086/590566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Cornely OA, Hoenigl M, Lass-Flörl C, et al. Defining breakthrough invasive fungal infection–position paper of the mycoses study group education and research consortium and the European Confederation of Medical Mycology. Mycoses. Blackwell Publishing Ltd; 2019. p. 716–729. [DOI] [PMC free article] [PubMed]
- 8.Medical Dictionary for Regulatory Activities. Common terminology criteria for adverse events (CTCAE) [Internet]. 2009. Available from: http://www.meddramsso.com.
- 9.Arrieta AC, Neely M, Day JC, et al. Safety, tolerability, and population pharmacokinetics of intravenous and oral isavuconazonium sulfate in pediatric patients. Antimicrob Agents Chemother. 2021;65(8):1–12. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Segers H, Deville JG, Muller WJ, et al. Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial. Antimicrob Agents Chemother. 2024. 10.1128/aac.00484-24. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11.European Medicines Agency (EMA). CRESEMBA, isavuconazole [Internet]. 2025 [cited 2025 Nov 18]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba#:~:text=Cresemba%20is%20an%20antifungal%20medicine,amphotericin%20B%2C%20is%20not%20suitable.
- 12.Food and Drug Administration (FDA). CRESEMBA® (isavuconazonium sulfate) [Internet]. 2025 [cited 2026 Jan 22]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/207500s016,207501s016lbl.pdf.
- 13.Alali M, Balsara K, Khaitan A, et al. Successful isavuconazole salvage therapy for cerebral mucormycosis in a child with relapsed leukemia: a light in the dark tunnel. Pediatr Blood Cancer. 2023. 10.1002/pbc.29807. [DOI] [PubMed] [Google Scholar]
- 14.Ashkenazi-Hoffnung L, Bilavsky E, Levy I, et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients. Pediatr Infect Dis J. 2020;39(8):718–24. [DOI] [PubMed] [Google Scholar]
- 15.Barg AA, Malkiel S, Bartuv M, et al. Successful treatment of invasive mucormycosis with isavuconazole in pediatric patients. Pediatr Blood Cancer. 2018. 10.1002/pbc.27281. [DOI] [PubMed] [Google Scholar]
- 16.Brivio E, Verna M, Migliorino GM, et al. Isavuconazole-induced acute liver failure in a pediatric patient with invasive aspergillosis. Pediatr Infect Dis J. 2019;38(10):1035–7. [DOI] [PubMed] [Google Scholar]
- 17.Bury D, Wolfs TFW, Heine R, et al. Pharmacokinetic investigations of isavuconazole in paediatric cancer patients show reduced exposure of isavuconazole after opening capsules for administration via a nasogastric tube. J Antimicrob Chemother. 2023;78(12):2886–9. [DOI] [PubMed] [Google Scholar]
- 18.Castagnola E, Mesini A, Saffioti C, et al. Intravenous isavuconazole can be administered 5 days-a-week. A possibility suggested by a real-life observation. J Chemotherapy. 2020; 32(4): 217–18. [DOI] [PubMed]
- 19.Cornu M, Bruno B, Loridant S, et al. Successful outcome of disseminated mucormycosis in a 3-year-old child suffering from acute leukaemia: the role of isavuconazole? A case report. BMC Pharmacol Toxicol. 2018;19(1):1–5. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.De Leonardis F, Novielli C, Giannico B, et al. Isavuconazole treatment of cerebral and pulmonary aspergillosis in a pediatric patient with acute lymphoblastic leukemia: case report and review of literature. J Pediatr Hematol Oncol. 2020;42(6):E469–71. [DOI] [PubMed] [Google Scholar]
- 21.Elhence H, Mongkolrattanothai K, Mohandas S, et al. Isavuconazole pharmacokinetics and pharmacodynamics in children. Pharmaceutics. 2023. 10.3390/pharmaceutics15010075. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Ferdjallah A, Nelson KM, Meyer K, et al. Isavuconazonium sulfate use in multi-modal management of invasive mucormycosis in four pediatric allogeneic hematopoietic cell transplant patients. J Pediatr Pharmacol Ther. 2021;26(8):863–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Naeem F, Laningham F, Kuzmic B, et al. Isavuconazole as salvage therapy for refractory pediatric coccidioidal meningitis. Pediatr Infect Dis J. 2021;40(3):E128–31. [DOI] [PubMed] [Google Scholar]
- 24.Garner LM, Echols CD, Wilson WS. Enteral tube administration of isavuconazole in a pediatric patient. Pediatr Blood Cancer. 2021;68(9):e29108. [DOI] [PubMed]
- 25.Fernández Ledesma B, Mendoza-Palomar N, Melendo Pérez S, et al. Isavuconazole use and TDM in real-world pediatric practice. Antimicrob Agents Chemother. 2023;67(12):e0082923. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Loeffen YGT, Scharloo F, Goemans BF, et al. Mucormycosis in children with hematologic malignancies: a case series and review of the literature. Pediatr Infect Dis J. 2022;41(9):E369–76. [DOI] [PubMed]
- 27.Mendoza-Palomar N, Melendo-Pérez S, Balcells J, et al. Influenza-associated disseminated aspergillosis in a 9-year-old girl requiring ECMO support. J Fungi. 2021. 10.3390/jof7090726. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 28.Nemoto H, Hino M, Aoki T, et al. Effectiveness of isavuconazole in invasive cerebral aspergillosis during hematopoietic stem cell transplantation in a pediatric patient with myelodysplastic syndrome: a case report. J Infect Chemother. 2025. 10.1016/j.jiac.2024.07.018. [DOI] [PubMed] [Google Scholar]
- 29.Pomorska A, Malecka A, Jaworski R, et al. Isavuconazole in a successful combination treatment of disseminated mucormycosis in a child with acute lymphoblastic leukaemia and generalized haemochromatosis: a case report and review of the literature. Mycopathologia. 2019;184(1):81–8. [DOI] [PubMed] [Google Scholar]
- 30.Shah H, Chisena E, Nguyen B, et al. Successful management of mucormycosis infection secondary to motor vehicle accident in a healthy adolescent: a case report. Med Mycol Case Rep. 2022;38:36–40. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Sosnowska-Sienkiewicz P, Błaszczyk K, Kubisiak-Rzepczyk H, et al. How to treat a child with a concurrent diagnosis of leukemia and generalized mucormycosis? Case report. Front Med (Lausanne). 2022;9:844880. [DOI] [PMC free article] [PubMed]
- 32.Styczynski J, Czyzewski K, Demidowicz E, et al. Isavuconazole in treatment of invasive fungal disease in children with malignancy or undergoing cellular therapy. Leuk Lymphoma. 2025;66(2):333–6. [DOI] [PubMed] [Google Scholar]
- 33.Zimmermann P, Brethon B, Roupret-Serzec J, et al. Isavuconazole treatment for invasive fungal infections in pediatric patients. Pharmaceuticals (Basel). 2022;15(3):375. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 34.Kunvarjee B, Siver M, Mathew S, et al. Characterization of the use and efficacy of isavuconazonium sulfate in a pediatric oncology and stem cell transplant population: a single institution retrospective review. J Pediatr Hematol Oncol. 2024;46(2):E143–6. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Mendoza-Palomar N, Simó Nebot S, Roig-Soria L, et al. Real-life use of isavuconazole in Spanish children and adolescents. J Antimicrob Chemother. 2025. 10.1093/jac/dkaf394. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Gatti M, Campoli C, Belotti T, et al. Real-world comparison of isavuconazole and voriconazole in terms of the need for dosage adjustments guided by clinical pharmacological advice during primary prophylaxis of invasive fungal infections in pediatric patients with hemato-oncological malignancies. Ther Drug Monit. 2022;44(6):641–50. [DOI] [PubMed] [Google Scholar]
- 37.Casalini G, Giacomelli A, Antinori S. The WHO fungal priority pathogens list: a crucial reappraisal to review the prioritisation. Lancet Microbe. 2024;5(7):717–24. [DOI] [PubMed]
- 38.Vu CA, Rana MM, Jacobs SE, et al. Isavuconazole for the prophylaxis and treatment of invasive fungal disease: a single-center experience. Transplant Infect Dis. 2020. 10.1111/tid.13469. [DOI] [PubMed] [Google Scholar]
- 39.Bose P, McCue D, Wiederhold NP, et al. Isavuconazole (ISAV) as primary anti-fungal prophylaxis in acute myeloid leukemia or myelodysplastic syndrome: an open-label, prospective study. Blood. 2018. 10.1182/blood-2018-99-111727. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 40.Pagano L, Maschmeyer G, Lamoth F, et al. Primary antifungal prophylaxis in hematological malignancies. Updated clinical practice guidelines by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2025. 10.1038/s41375-025-02586-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Maertens JA, Raad II, Marr KA, et al. Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): a phase 3, randomised-controlled, non-inferiority trial. Lancet. 2016;387(10020):760–9. [DOI] [PubMed] [Google Scholar]
- 42.Kaindl T, Andes D, Engelhardt M, et al. Variability and exposure-response relationships of isavuconazole plasma concentrations in the Phase 3 SECURE trial of patients with invasive mould diseases. J Antimicrob Chemother. 2019;74(3):761–7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 43.NCT03816176 ClinicalTrials gov I. A phase 2, open-label, non-comparative, multicenter study to evaluate the safety and tolerability, efficacy and pharmacokinetics of isavuconazonium sulfate for the treatment of invasive aspergillosis (IA) or invasive mucormycosis (IM) in pediatric subject.
- 44.Groll AH, Desai A, Han D, et al. Pharmacokinetic assessment of drug-drug interactions of isavuconazole with the immunosuppressants cyclosporine, mycophenolic acid, prednisolone, sirolimus, and tacrolimus in healthy adults. Clin Pharmacol Drug Dev. 2017;6(1):76–85. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.Lehrnbecher T, Fisher BT, Phillips B, et al. Clinical practice guideline for systemic antifungal prophylaxis in pediatric patients with cancer and hematopoietic stem-cell transplantation recipients. J Clin Oncol. 2020;38(27):3205-16 [DOI] [PMC free article] [PubMed]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
